



HHS Public Access

Author manuscript

WIREs Mech Dis. Author manuscript; available in PMC 2023 January 23.

Published in final edited form as:

WIREs Mech Dis. 2023 January ; 15(1): e1582. doi:10.1002/wsbm.1582.

Fluids and flows in brain cancer and neurological disorders

Peng Jin,

Jennifer M. Munson

Fralin Biomedical Research Institute, Department of Biomedical Engineering and Mechanics, Virginia Polytechnic Institute and State University, Roanoke, Virginia, USA

Abstract

Interstitial fluid (IF) and cerebrospinal fluid (CSF) are an integral part of the brain, serving to cushion and protect the brain parenchymal cells against damage and aid in their function. The brain IF contains various ions, nutrients, waste products, peptides, hormones, and neurotransmitters. IF moves primarily by pressure-dependent bulk flow through brain parenchyma, draining into the ventricular CSF. The brain ventricles and subarachnoid spaces are filled with CSF which circulates through the perivascular spaces. It also flows into the IF space regulated, in part, by aquaporin channels, removing waste solutes through a process of IF-CSF mixing. During disease development, the composition, flow, and volume of these fluids changes and can lead to brain cell dysfunction. With the improvement of imaging technology and the help of genomic profiling, more information has been and can be obtained from brain fluids; however, the role of CSF and IF in brain cancer and neurobiological disease is still limited. Here we outline recent advances of our knowledge of brain fluid flow in cancer and neurodegenerative disease based on our understanding of its dynamics and composition.

This article is categorized under:

Cancer > Biomedical Engineering

Neurological Diseases > Biomedical Engineering

Keywords

brain cancer; fluid flow; neuroscience

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](#) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Correspondence Jennifer M. Munson, Room 1210, 4 Riverside Circle, Roanoke, VA 24016, USA. jm4kt@vt.edu.

AUTHOR CONTRIBUTIONS

Peng Jin: Conceptualization (equal); writing – original draft (equal); writing – review and editing (equal). **Jennifer Munson:** Conceptualization (equal); funding acquisition (lead); project administration (lead); resources (lead); supervision (lead); writing – original draft (equal); writing – review and editing (equal).

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

RELATED WIREs ARTICLE

[Integrative physical oncology](#)

1 | INTRODUCTION

1.1 | Brain fluid compartments

The brain interstitial space is a dynamic location between the parenchymal cells and vasculature, which provides the fluid and structural environment to support cellular functions. There are three different types of fluid circulating in the brain involved in maintenance and homeostasis. (1) The cerebral blood, primarily in the cerebral veins and intracranial arteries, plays an important role in maintaining proper brain perfusion, providing substrates necessary for proper neuronal function, and removing the waste products of metabolism (Fantini et al., 2016). (2) The cerebrospinal fluid (CSF) is a transparent fluid formed within the cerebral ventricles and exists in both the spinal and intracranial compartments (Davson et al., 1970). The CSF is continuously secreted by the choroid plexus, flowing into the brain ventricular space at a constant rate, and circulates in the subarachnoid space and spinal cord (Brown et al., 2004; Damkier et al., 2013). (3) Interstitial fluid (IF) is a fluid residing within the brain interstitial spaces between the parenchymal cells and extracellular matrix. The IF contains a variety of organic compounds and inorganic substances such as neurotransmitters, sugars, amino acids, coenzymes, hormones, salts, and other cellular products (Nakada & Kwee, 2019).

These three fluids are interconnected, however their roles, actions, and responses can vary in different disease states. In this review, we intend to summarize recent research illuminating how CSF and IF regulate brain function during disease development and progression. Beyond the role of a protective fluid cushion and sink for waste, we will focus on diagnosis, treatment, and prevention in central nervous system (CNS)-related diseases.

1.2 | Physiological function of fluids

The CSF has several important functions including providing physical protection, nourishing cells and tissues within the brain, and removing waste from the CNS (Pollay, 2010). Physical protection by the CSF is most apparent in its function as a shock absorber, buffering the impact of brain movement against the skull during impact (Sakka et al., 2011; Telano & Baker, 2021). The CSF also provides buoyancy to the brain effectively reducing its weight, and allowing the brain to maintain its shape (Telano & Baker, 2021). Since the CSF is continuously produced by the choroid plexus, there is a constant clean source of fluid introduced into the rest of the brain. Waste products that are originally produced through brain cell metabolism or synaptic activity are diluted in CSF and subsequently removed via the glymphatic system (Damkier et al., 2013; Huff et al., 2021; Segal, 1993). The glymphatic system is a major drainage pathway within the cortex that comprises a perivascular network, serving to transport CSF through the parenchyma (Iliff et al., 2012; Nedergaard, 2013). It is closely connected to a downstream extraneural drainage network, including meningeal lymphatics, cranial nerves, and large vessels that exit the skull (Louveau et al., 2015; Ma et al., 2017) (Figure 1). The CSF also flows into the interstitial space along this periarterial glymphatic compartment regulated, in part, by the aquaporin-4 (AQP4) water channel in astrocytic end-feet (Benveniste et al., 2019; Mestre, Hablitz, et al., 2018). The CSF carries glucose, proteins, lipids, and electrolytes, providing essential nutrients to CNS through these routes (Veening & Barendregt, 2010). The main

function of IF is, providing a “bath” around the brain parenchyma cells. Similarly to CSF function, the IF plays a role in transferring the energy needed for brain cell metabolism while also providing the specific mechanical environment for the physiological activities of the interstitial cells and extracellular matrix (Aukland et al., 1994; Cirrito et al., 2003; Hladky & Barrand, 2014; Kvietyts & Granger, 2010). Moreover, the IF mixes with CSF as it drives the clearance of metabolites and waste products away from the periarterial space toward the perivenous space, finally excreting it through the meningeal lymphatic vessels to the cervical lymph nodes (Benveniste et al., 2017; Hirose et al., 2021). The nature of the IF flows are still being elucidated and thus, methods to image and analyze all the flows in the brain are essential to an understanding of healthy and diseased brain.

1.3 | Fluid flow measurement

Traditional CSF flow measurement is based on invasive procedures such as intracranial pressure monitoring, radioisotope studies, myelographies or lumbar puncture, all of which offer important information about different disorders of the CNS through detection of CSF abnormalities (Korbecki et al., 2019). The rapid development of imaging technology has provided noninvasive methods for assessing dynamic fluid flow, for example, phase-contrast magnetic resonance imaging (PC-MRI), arterial spin labeling (ASL), and 3D-SPACE. The PC-MRI technique is one of the most common procedures for qualitative and quantitative evaluation of CSF changes (Enzmann & Pelc, 1991; Nitz et al., 1992), and combined with other advanced brain imaging technology, provides a useful tool for measuring fluid flow dynamics in aging (Spijkerman et al., 2019), idiopathic intracranial hypertension (IIH) (Capel et al., 2018), brain atrophy (BA) (Yousef et al., 2016), and syringomyelia (Yeo et al., 2017). In clinical studies, PC-MRI has acquired information on the physiology of the normal CSF circulation, in addition to diseases such as aqueductal stenosis (Mohammad et al., 2019), chiari malformation (Smith et al., 2015) and normal pressure hydrocephalus (NPH) (Bradley, 2015; Tawfik et al., 2017), where flows are disrupted.

The IF is an important part of the brain interstitial system comprising approximately 20% of the total brain volume (C. Shi et al., 2015). Unlike with CSF, which is largely detected in the ventricles or other spaces around the brain, the IF is dispersed throughout the brain parenchyma, making it more difficult to access and image. The IF is dynamically distributed between the interstitial space and the brain microvasculature, within exceptionally confined spaces between the parenchymal cells and extracellular matrix. Additionally, the flow of IF is much slower than that of the CSF, often 100 times so (Mestre, Tithof, et al., 2018). Therefore, measurement of IF flow is more difficult than measurement of CSF flow with current methods. Techniques to measure or image the brain IF flow include tracer-based MRI techniques (Benveniste & Blackband, 2002; Han et al., 2014), intravital microscopy (Bedussi et al., 2018), nuclear medicine (Siekkinen et al., 2020) (e.g., positron emission tomography (PET), single-photon emission computerized tomography (SPECT), autoradiography), and transcranial Doppler (W.-J. Lee et al., 2019) (Table 1). Recently, tracer-based imaging was used in animal models of disease and human patients (Chatterjee et al., 2021; Da Mesquita et al., 2018; Kingsmore et al., 2018; Lv et al., 2017). The IF flow and drainage pathways were measured after injection of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA), and sequential T1-weighted dynamic contrast enhanced MRI

(DCE-MRI) to track IF movement (Han et al., 2012), which was applied in tumor bearing rat and mouse models, and translated to human glioma showing heterogeneous flow paths in and around brain tumors (Chatterjee et al., 2021; Guan et al., 2018; Kingsmore et al., 2018).

2 | FLUIDS AND FLOWS IN BRAIN CANCER

2.1 | Fluid flow and glioma invasion

Fluid flow is in intimate contact with the brain tumor microenvironment, particularly at the invasive edges of these cancers. The role of fluid flow in cancers has been most studied in gliomas, particularly in glioblastoma, the most deadly and common of brain tumors. IF flow has been found to increase and influence tumor cell invasion, proliferation and differentiation in noncentral nervous system cancers (Haessler et al., 2012; Polacheck et al., 2011; Shah et al., 2015). As early as 30 years ago, several investigators measured interstitial pressure of brain tumors finding that it was significantly elevated compared with normal tissues (Boucher & Jain, 1992; Gutmann et al., 1992; I. Lee et al., 1992). This pressure differential results in flow of IF (Munson & Shieh, 2014) from the tumor into surrounding normal tissue. As a result of predicting and measuring, it is estimated IF velocities range from 0.1 to 3 $\mu\text{m/s}$ in animal models, depending on the size and location of tumors (Heldin et al., 2004). Using in vitro models of disease, increased IF velocities at the tumor edges can lead to invasion of tumor cells through two as yet identified mechanisms: gradient formation and mechanotransduction. Transcellular gradients form due to IF flow carrying cell-secreted proteins downstream of tumor cells where they bind to the extracellular matrix (Fleury et al., 2006; Stine & Munson, 2022). This transcellular gradient can promote directional metastasis of glioma cells by a mechanism named “autologous chemotaxis” (Fleury et al., 2006). In glioma, CXCL12 and its receptor CXCR4 have been shown to contribute to this mechanism of IF-mediated invasion both in vitro and in vivo (Cornelison et al., 2018; Kingsmore et al., 2016; Munson et al., 2013). CD44, a major receptor on many glioma cells, can also mediate flow-increased invasion through interactions with the extracellular matrix (Kingsmore et al., 2016). Qazi et al. (2011) demonstrated that fluid shear stress is an important factor influencing mechanotransduction-induced invasion through activation of matrix metalloproteinases (MMPs) leading to matrix degradation and subsequent cellular migration. Taken together, there are multiple governing mechanisms that mediate increases in glioma invasion by elevated IF flow, and likely, these mechanisms work in concert in the brain tumor microenvironment, enhancing malignancy of disease.

The IF constantly exchanges with CSF thus providing a reservoir for pro-tumorigenic proteins secreted by brain cancer cells during glioma progression. A recent clinical study showed that the expression of vitronectin, a known promoter of glioma invasion, in glioma patient tumor samples corresponded to levels detected in CSF samples (Fukushima et al., 2007). This study indicates that not only is the CSF is closely related to brain glioma cells during tumor development, it may provide essential factors that promote tumor spread. In another clinical study of CSF samples, researchers found that MMPs and their derivatives are markedly increased in glioma patients when compared to healthy patients (Friedberg et al., 1998). These findings showed MMP-2 and MMP-9 are directly transmitted to tumor cells via the glymphatic system resulting in increased invasion. Moreover, various activated

complex genes have been identified in the CSF including malignant promoter genes known to promote a more malignant tumor phenotype (Carrano et al., 2021). In terms of glioma invasion, the CSF has not been widely used in clinical practice so far for detection or assessment. However, as our knowledge grows surrounding the interactions of CSF with tumor invasion and progression, it offers a potentially important tool in clinical diagnosis and prognosis.

2.2 | Fluid biomarkers in glioma diagnosis

Conventional diagnosis of glioma relies on clinical presentation, including neuroimaging and histopathological analysis. With the development of technology in the field of neuroimaging, neurosurgery, oncology, and radiotherapy, the survival of glioma patients has improved, though only marginally for the most malignant disease (Osman, 2019; Tan et al., 2020). There is the need and opportunity to identify biomarkers to aid in diagnosis, prognosis and tracking of treatment outcomes. The CSF is an important source of potential molecular biomarkers, mostly collected by lumbar puncture or surgery around the brain area. Most analysis has thus far focused on detecting (1) cells (i.e., detecting circulating tumor cells); (2) cell-free tumor DNA (ctDNA); (3) nonprotein-coding transcripts (microRNA and noncoding RNA); or (4) tumor-related metabolites (Figure 2).

CSF cytology provides important initial information across a spectrum of pathologic conditions in glioma patients. In a recent clinical trial neoplastic meningitis from solid tumor was diagnosed by identification of circulating tumor cells (CTCs) in the CSF, which was analyzed by rare cell-capture technology (Nayak et al., 2013). Large-scale studies have reported several tumor types found through CSF sampling such as primitive neuroectodermal tumors (PNETs), high-grade infiltrating glioma, atypical teratoid/rhabdoid tumors (AT/RTs), and low-grade glioma (Ho et al., 2015). These tumor cells initially discovered in the CSF are the earliest meaningful sign for patients in that their detection can enable to clinicians react quickly with the most relevant therapy at earlier stages in tumor development and treatment.

The CSF is a rich and reliable source of ctDNA, and the analysis of this biomarker can characterize and monitor primary and metastatic brain tumors. The ctDNA is not only present in the CSF but also found in the blood of malignant tumor patients. However, the amount of ctDNA in the blood is limited in primary brain tumor patients, with only a minority of patients yielding detectable levels. Thus, in primary tumor patients, the ctDNA is better collected and analyzed from the CSF (Bettegowda et al., 2014; Zill et al., 2018). According to a recently published report, results leveraging deep sequencing of ctDNA obtained from the CSF of glioma patients, indicated that tumor-specific genes were altered (Pan et al., 2019). Interestingly, these tumor-specific gene alterations matched those obtained from samples of the primary tumor. Therefore, the ctDNA extracted from CSF may be used as a surrogate for tumor typing and analysis.

MicroRNAs (miRNA) are noncoding RNAs (ncRNA) of short length, consisting of 18–25 nucleotides (Lagos-Quintana et al., 2001) and are key biological factors in organism development, cell specialization, and homeostasis. Circulating miRNAs exist in almost all human body fluids including blood, serum, urine, saliva, tears, and CSF (Weber et al.,

2010). A number of clinical studies have shown that heightened expression of specific miRNAs is closely associated with malignant tumors, in particular the miRNAs contained in the CSF of brain tumor patients show promise as diagnostic biomarkers (Grotzer et al., 2015; R. Shi et al., 2015). One study in particular identified that metastatic tumor miRNA (i.e., miRNA-125a, miRNA-125b and miRNA-1290) was over-expressed in CSF samples, corresponding to expression levels in the tumor. These fundamental studies showed that miRNA-125a, miRNA-125b and miRNA-1290 can be diagnostic markers for metastatic tumors. In addition, the levels of miRNA-15b and miRNA-21 in CSF from patients with tumors are highly specific in comparison to the miRNAs collected from healthy patients (Baraniskin et al., 2012). Therefore, there is a particular subset of miRNAs that can readily identify brain tumors in clinical practice.

Cancer metabolism research has rapidly expanded in recent years. Metabolic profiling of CSF is used as a tool for diagnosing cancers in patients. Several different groups have collected samples from biofluids and tissues and have used nuclear magnetic resonance (NMR) or mass spectrometry to profile metabolites (Locasale et al., 2012; Nakamizo et al., 2013). According to this type of metabolic profiling analysis, detected metabolites in the CSF of tumor patients and nontumor patients differ (Hirayama et al., 2009). Similarly, metabolites, including specifically lactic acid and choline, in the CSF from high grade glioma patients were significantly increased compared with low grade glioma (Nakamizo et al., 2013). Together, the metabolite biomarkers identified in the CSF of brain tumor patients could provide clinically relevant biomarkers, assisting with diagnosis and providing valuable information for underlying mechanisms surrounding progression to malignant disease.

2.3 | Fluid flow in glioma therapy

Brain fluid flow as an integral component of the tumor microenvironment, plays an important role in the treatment of tumors. It has been detected and computationally modeled that elevated interstitial fluid pressure (IFP) in solid tumors results in IF flows in the surrounding tumor microenvironment (Boucher & Jain, 1992). High IFP has negative implications for chemotherapeutic treatment in that it can limit transport from the tumor microvasculature into the surrounding parenchyma, termed the blood-tumor barrier. Outward convection can also lead to drug removal from the peripheral regions reducing residence time with tumor cells (Welter & Rieger, 2013). Transport of small molecule (<1 kDa) drugs is diffusion-limited, while larger molecules and nanoparticles are subject to the convective flows induced by IFP gradients. IF flow can also be advantageous in terms of getting larger therapeutics through the interstitial space via convective forces. A method called convection-enhanced delivery (CED) involves the continuous infusion of therapeutic agents under positive pressure via implanted catheters (Anderson et al., 2013; Barua et al., 2013). CED can overcome heightened interstitial pressures, bypass the blood brain barrier, and enhance interstitial transport with minimal systemic toxicity while providing higher dosing to the tumor. These alterations of fluid flow via biophysical intervention offer one avenue for treating cancer and overcoming delivery challenges. Additionally, the molecules related to fluid flow responses of tumor cells may serve as targets for its treatment. Several molecules involving IF flow-enhanced invasion have been identified and are in various stages of development preclinically and clinically (Cornelison et al., 2018; Munson et al., 2013;

Shields et al., 2007). These molecules provide conduits to regulate the negative effects of IF flow on cancer progression. Overall, the CSF and IF are a rich biological information source, including circulating tumor cells, ctDNA, miRNAs, proteins and exosomes. Along with rapidly increasing sensitivity and specificity of these analyses, better understanding of the nature of these flows and interactions with tumor cells, and correlations to clinical parameters we expect in the near future, these clinically relevant markers could potentially translate to therapeutic targets.

3 | FLUIDS AND FLOWS IN ALZHEIMER'S DISEASE

3.1 | The role of fluid flow in Alzheimer's disease

Alzheimer's disease (AD) is a leading cause of dementia, and is pathologically defined by the presence of amyloid- β ($A\beta$) plaques and Tau-containing neurofibrillary tangles in the brain parenchyma. $A\beta$ is removed from the brain by various clearance systems, including proteolytic degradation (Saido & Leissring, 2012), blood-brain barrier (BBB) transport (Deane et al., 2003), IF bulk flow (Bedussi et al., 2018), and CSF absorption into the circulatory (Bateman et al., 2006) and lymphatic systems (Tarasoff-Conway et al., 2015). As early as 20 years ago, a handful of in vivo studies indicated that the majority of $A\beta$ plaques are removed by the BBB, and only a small amount of them are cleared by IF bulk flow (Shibata et al., 2000). However, through advancement of imaging technology and careful experimental work focused on IF bulk flow through the glymphatic system, the role of IF is larger than previously thought (Hablitz et al., 2020; Iliff et al., 2012; Xie et al., 2013). AQP4, one of the membrane-bound protein family, is expressed in the end-feet of astrocytes (Papadopoulos & Verkman, 2013). AQP4 plays a role in clearing interstitial Tau protein and $A\beta$ and as such, dysfunction of AQP4 interferes with this clearance through changes in IF bulk flow within the glymphatic system in murine models of Alzheimer's Disease (Iliff et al., 2012; Silva et al., 2021). The CSF flow clears large proteins such as $A\beta$ and Tau to the perivenous space through a dilution process with IF, finally removing them from the brain. These flows also clear through the meningeal lymphatics, found surrounding the brain, and into cervical lymph nodes (Eide et al., 2018; D. S. Lee et al., 2020). In animal models of Alzheimer's Disease, these vessels shrink, but delivery of Vascular Endothelial Growth Factor-C, a lymphatic-specific growth factor, can induce vessel growth in aging mice, and restore cognitive function (Da Mesquita et al., 2018).

3.2 | Fluid biomarkers in AD

The clinical diagnosis of AD is usually based on excluding other systemic disease and mainly diagnosed through cognitive ability or behavioral tests (Knopman et al., 2001). Recently, CSF biomarkers have been increasingly used in clinical trials for early diagnosis of AD. The CSF amyloid beta ($A\beta$)₁₋₄₂ (Hansson et al., 2019), total Tau (T-Tau) (Schröder et al., 2008), and phosphorylated Tau (P-Tau) (Wattmo et al., 2020) have been assessed in numerous clinical studies. The total concentration of CSF $A\beta$ ₁₋₄₂ decreases over time in AD patients, while the Tau and phosphorylated Tau protein levels in CSF become elevated later in the pathophysiological process (Buchhave et al., 2012). As such, the CSF Tau protein concentration is highly correlated with cognitive impairment as compared to $A\beta$ (Savva et al., 2009). Several large multicenter clinical studies reported by Hansson et al.

(2006), Buchhave et al. (2012) and Mattsson et al. (2009) showed that CSF A β 42, CSF T-Tau, and CSF P-Tau identify emerging AD with good accuracy, further indicating that these markers could diagnose AD at an early stage.

4 | FLUIDS AND FLOWS IN OTHER DISORDERS

Abnormal CSF circulatory dynamics can be affected in several CNS diseases including increased intracranial pressure (ICP), hydrocephalus (Bradley, 2015), idiopathic intracranial hypertension (Virdee et al., 2020), traumatic brain injury (Buttram et al., 2007), stroke (Simats et al., 2018), post-traumatic syringomyelia (Yeo et al., 2017) and brain tumors (Table 2).

4.1 | Hydrocephalus

Hydrocephalus is the buildup of fluid in the ventricles deep within the brain characterized by excessive accumulation of CSF, the result of disturbances in normal secretion or absorption mechanisms (Rekate, 2009). Early research suggested that hydrocephalus was caused by large ICP differentials between the ventricles and the spinal subarachnoid spaces, named noncommunicating hydrocephalus (Hakim et al., 1976). This elevated ICP caused CSF leaks, leading to abnormal drainage and/or CSF flows. Another type of hydrocephalus is communicating hydrocephalus (normal pressure hydrocephalus), which by definition does not result in increased ICP, but it usually co-exists with noncommunicating hydrocephalus. In adults, hydrocephalus commonly happens in patients with a history of strokes, trauma, infections, hemorrhage or tumors (Bodilsen et al., 2013; Bu et al., 2016; Fischer et al., 2014). In the clinic, physicians mainly use neurological exams and noninvasive brain imaging for diagnosis (Koleva & De Jesus, 2022). The most common treatment for hydrocephalus involves the surgical implantation of a shunt, followed by endoscopic third ventriculostomy. Several studies have indicated that aquaporin channels are involved in the pathophysiology of hydrocephalus through engagement of their role in fluid homeostasis (Desai et al., 2016; Hemley et al., 2012; Verkman et al., 2017). Animal studies have demonstrated that AQP1 can regulate the secretion and osmosis of CSF to control hydrocephalus (Wang et al., 2011). These results support the possibility of targeted gene therapy to provide nonsurgical management of hydrocephalus.

4.2 | Idiopathic intracranial hypertension

Idiopathic intracranial hypertension (IIH) is a syndrome characterized by elevated CSF pressure of unknown mechanism and has a high rate of occurrence. Its pathological characteristics are (1) increased CSF production, (2) reduced CSF absorption, and (3) hormonal dysregulation (Hornby et al., 2018; Mollan et al., 2016). Previous animal studies have reported AQP1 expression is closely related to raised ICP through increased CSF production (Stiebel-Kalish et al., 2013), however there is no direct evidence that AQP1 plays the same role in humans. Blood clotting abnormalities have been reported in IIH patients and may indirectly explain the impaired CSF drainage (Sussman et al., 1997). Moreover, in a recent study female IIH patients present increased hormone levels such as serum testosterone, CSF testosterone and androstenedione (O'Reilly et al., 2019). Androgens are known to modulate CSF secretion via the choroid plexus (Santos et al., 2017), a potential

driver of increased brain pressure, indicating the potential of targeting these hormones to resolve this condition.

4.3 | Traumatic brain injury

Traumatic brain injury (TBI) results when a person suffers a blow to the head often leading to disruption of normal brain function, severe injury or death. One common complication in TBI patients is CSF leakage. CSF leakage occurs most often in patients who have suffered head injuries involving skull fractures (Friedman et al., 2001). Patients with TBI can also develop edema, leading to increased ICP and resultant abnormal CSF flow (Bothwell et al., 2019). In rodent models of TBI, glymphatic flow is disrupted with TBI, with repetitive TBI resulting in accumulation of aberrant protein within the glymphatic spaces (Christensen et al., 2020; Iliff et al., 2014; Li et al., 2020). Similarly, disruption of the meningeal lymphatic drainage, thereby reducing the ability of flow to move through and exit the brain, results in worsened symptomology and damage after TBI (Bolte et al., 2020). To our knowledge, there have not yet been any CSF biomarkers that can be used clinically to diagnose TBI. However, several researchers have reported that inflammatory cytokines, such as IL-6, IL-8, and IL-10 are elevated in CSF after severe TBI (Buttram et al., 2007; Kirchhoff et al., 2008; Semple et al., 2010).

4.4 | Ischemic stroke

Stroke commonly occurs when the blood supply to part of the brain is interrupted or reduced, leading to reduced oxygen and nutrient supply. Fluid flow inherently is disrupted when a stroke occurs, as the blood brain barrier is broken down, often causing influx of blood into the tissue. Disrupted flow often results in cerebral edema (Arbel-Ornath et al., 2013; Dhar et al., 2020), and this has been related to reduced drainage via both glymphatics and the meningeal lymphatics (reviewed in Chen et al., 2021; Ji et al., 2021). The CSF is structurally positioned such that it can reflect the immediate immunological changes occurring within ischemic brain tissue. However, in clinical practice using the CSF for diagnosis of stroke is challenging, primarily limited by collection since it requires an invasive procedure that can be difficult to perform in emergency situations. Nevertheless, CSF evaluation could potentially provide additional information for the further pathogenic alterations that occur post initial event. According to published data, CSF proinflammatory cytokine levels, such as IL-6, IL-1 β , and TNF- α , are elevated in stroke patients 6 h after onset as compared to a control group (Beridze et al., 2011). These cytokines can be used to assess the progression of stroke. Moreover, using CT-based imaging techniques to measure the volume of CSF in patients with stroke can be used to indirectly evaluate the progression of stroke via cerebral edema severity at peak swelling (Dhar et al., 2016, 2020). These clinical studies may contribute to a more complete interpretation of stroke pathology through the assessment of the CSF.

4.5 | Syringomyelia

Post-traumatic Syringomyelia (PTS) is a particular type of syringomyelia which along with presence of abnormal fluid filled cavities (syringes) after spinal cord injury. PTS generally develops within 5 years after the initial spinal cord injury and impairs CSF circulation (Carroll & Brackenridge, 2005). As early as the 1990s, the clinical studies have

shown that using MRI diagnosis of PTS with measurement of CSF flow in the cavity (Tobimatsu et al., 1995). The CSF flow can be classified into two main categories in the spinal subarachnoid space: pulsatile caudal and rostral flow (Enzmann & Pelc, 1991). Yeo et al. (2017) performed CSF velocity measurements in patients with a syringe with spinal cord injuries via T1-weighted MRI, and found that the average caudal velocities in the syringomyelia patients were 65% lower than in healthy individuals (Yeo et al., 2017). Several different surgical treatments have been favored for the treatment of PTS including laminectomy and opening-up of spinal CSF pathways to restore normal CSF flow dynamics (Falci et al., 2009; Karam et al., 2014; Vaquero et al., 2017). Overall, the prognosis after surgery is not very reliable with current treatment strategies, and thus further prospective work is required to correlate radiographic measures for diagnosing PTS early in its evolution. Further new therapies are being pursued and necessary including inclusion of stem cell therapies (Vaquero et al., 2017),

5 | CONCLUSIONS AND PERSPECTIVE

Fluid flow is an important part of the brain, both functionally and structurally. Despite studies and clinical trials showing that these fluids play a significant role in the development of brain cancer and neurological diseases, they are still relatively poorly understood and implemented. Thus far, most studies have focused on independent fluid flow either of the CSF or IF. However, the precise mechanisms that underlie CSF-IF exchange are yet to be fully defined though this remains an active area of research. As we gain more precise measurements of CSF and IF flow dynamics via MRI in normal and diseased brains, we may see that tracking fluid flow during brain cancer development or neurodegenerative disease progression may offer a useful tool in the diagnostic arsenal. Recently, Kingsmore et al. (2018) leveraged current MRI techniques by applying mass transport principles to calculate IF rates and directions in and around brain tumors. This was subsequently applied to patients with glioblastoma and showed correlations with survival in glioblastoma (Chatterjee et al., 2021). Similarly, this type of MRI technology can offer insight in other neurological disorders (Da Mesquita et al., 2018).

Compared with IF, CSF analysis has been more actively pursued in the clinic. Biomarkers within the CSF have shown potential in clinical trials. In brain cancer, collection of CSF samples from patients provides a resource for biomarker discovery, with the potential to provide patients with personalized and adaptive treatment. In addition, CSF biomarkers have shown good diagnostic performance for mild cognitive impairment in AD patients (Kang et al., 2014). However, there is still work to be done on standardization metrics for these biomarkers prior to clinical implementation. On the contrary, IF is a unique brain fluid that contains biomarkers that may have clinical utility and physiological implications, but sampling of IF for clinical applications has been limited due to a lack of straightforward methods to collect IF from brain. Moreover, existing *in vivo* tools do not enable measurement of large rarely encountered molecules, such as proteins and neuropeptides, in the fluid. Thus, generation of a complete picture of the neurochemistry of these fluids would be a foundational advance in the future to better understand the whole profile of fluids in the brain. Together, there is a need for more widespread research on collection of IF and possible future clinical practice required less invasive sampling methods. Such

technological advances can further our knowledge of IF composition and hence, the clinical use of IF for diagnostic and treatment applications. Overall, the view of fluids in the brain holistically is essential to best understanding neurological diseases, including both their flows and their composition. The potential is high for discovery, development, and treatment of numerous conditions by examination of this untapped resource within the brain interstitial and ventricular spaces.

Funding information

National Institute on Aging, Grant/Award Number: RF1AG071661

FUNDING

Funding provided by the National Institute on Aging RF1AG071661 and the National Cancer Institute R37CA222563 to JMM.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

REFERENCES

- Ahmad N, Salama D, & Al-Haggar M (2021). MRI CSF flowmetry in evaluation of different neurological diseases. *Egyptian Journal of Radiology and Nuclear Medicine*, 52(1), 53. 10.1186/s43055-021-00429-w
- Akay R, Kamisli O, Kahraman A, Oner S, & Tecellioglu M (2015). Evaluation of aqueductal CSF flow dynamics with phase contrast cine MR imaging in idiopathic intracranial hypertension patients: Preliminary results. *European Review for Medical and Pharmacological Sciences*, 19(18), 3475–3479. [PubMed: 26439045]
- Anderson RCE, Kennedy B, Yanes CL, Garvin J, Needle M, Canoll P, Feldstein NA, & Bruce JN (2013). Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. *Journal of Neurosurgery. Pediatrics*, 11(3), 289–295. 10.3171/2012.10.PEDS12142 [PubMed: 23240851]
- Arbel-Ornath M, Hudry E, Eikermann-Haerter K, Hou S, Gregory JL, Zhao L, Betensky RA, Froesch MP, Greenberg SM, & Bacskaï BJ (2013). Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer's disease mouse models. *Acta Neuropathologica*, 126(3), 353–364. 10.1007/s00401-013-1145-2 [PubMed: 23818064]
- Attier-Zmudka J, Sérot J-M, Valluy J, Saffarini M, Macaret A-S, Diouf M, Dao S, Douadi Y, Malinowski KP, & Balédent O (2019). Decreased cerebrospinal fluid flow is associated with cognitive deficit in elderly patients. *Frontiers in Aging Neuroscience*, 11, 1–8. 10.3389/fnagi.2019.00087 [PubMed: 30740048]
- Aukland K, Bogusky RT, & Renkin EM (1994). Renal cortical interstitium and fluid absorption by peritubular capillaries. *The American Journal of Physiology*, 266(2 Pt 2), F175–F184. 10.1152/ajprenal.1994.266.2.F175 [PubMed: 8141318]
- Baraniskin A, Kuhnenn J, Schlegel U, Maghnouj A, Zöllner H, Schmiegell W, Hahn S, & Schroers R (2012). Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. *Neuro-Oncology*, 14(1), 29–33. 10.1093/neuonc/nor169 [PubMed: 21937590]
- Barua NU, Woolley M, Bienemann AS, Johnson DE, Lewis O, Wyatt MJ, Irving C, O'Sullivan S, Murray G, Fennelly C, Skinner P, & Gill SS (2013). Intermittent convection-enhanced delivery to the brain through a novel transcutaneous bone-anchored port. *Journal of Neuroscience Methods*, 214(2), 223–232. 10.1016/j.jneumeth.2013.02.007 [PubMed: 23419699]

- Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, & Holtzman DM (2006). Human amyloid- β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. *Nature Medicine*, 12(7), 856–861. 10.1038/nm1438
- Bedussi B., Almasian M., de Vos J., VanBavel E., & Bakker EN. (2018). Paravascular spaces at the brain surface: Low resistance pathways for cerebrospinal fluid flow. *Journal of Cerebral Blood Flow & Metabolism*, 38(4), 719–726. 10.1177/0271678X17737984 [PubMed: 29039724]
- Belal T, Al Tantawy A-E, Sherif FM, & Ramadan A (2020). Evaluation of cerebrospinal fluid flow dynamic changes in patients with idiopathic intracranial hypertension using phase contrast cine MR imaging. *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, 56(1), 94. 10.1186/s41983-020-00227-7
- Benveniste H, & Blackband S (2002). MR microscopy and high resolution small animal MRI: Applications in neuroscience research. *Progress in Neurobiology*, 67(5), 393–420. 10.1016/S0301-0082(02)00020-5 [PubMed: 12234501]
- Benveniste H, Lee H, & Volkow ND (2017). The Glymphatic pathway: Waste removal from the CNS via cerebrospinal fluid transport. *The Neuroscientist: A Review Journal Bringing Neurobiology, Neurology and Psychiatry*, 23(5), 454–465. 10.1177/1073858417691030 [PubMed: 28466758]
- Benveniste H, Liu X, Koundal S, Sanggaard S, Lee H, & Wardlaw J (2019). The glymphatic system and waste clearance with brain aging: A review. *Gerontology*, 65(2), 106–119. 10.1159/000490349 [PubMed: 29996134]
- Beridze M, Sanikidze T, Shakarishvilil R, Intskirveli N, & Bornstein NM (2011). Selected acute phase CSF factors in ischemic stroke: Findings and prognostic value. *BMC Neurology*, 11(1), 41. 10.1186/1471-2377-11-41 [PubMed: 21450100]
- Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, ... Diaz LA (2014). Detection of circulating tumor DNA in early- and late-stage human malignancies. *Science Translational Medicine*, 6(224), 224ra24. 10.1126/scitranslmed.3007094
- Bodilsen J, Schönheyder HC, & Nielsen H (2013). Hydrocephalus is a rare outcome in community-acquired bacterial meningitis in adults: A retrospective analysis. *BMC Infectious Diseases*, 13(1), 321. 10.1186/1471-2334-13-321 [PubMed: 23855442]
- Bolte AC, Dutta AB, Hurt ME, Smirnov I, Kovacs MA, McKee CA, Ennerfelt HE, Shapiro D, Nguyen BH, Frost EL, Lammert CR, Kipnis J, & Lukens JR (2020). Meningeal lymphatic dysfunction exacerbates traumatic brain injury pathogenesis. *Nature Communications*, 11(1), 4524. 10.1038/s41467-020-18113-4
- Bothwell SW, Janigro D, & Patabendige A (2019). Cerebrospinal fluid dynamics and intracranial pressure elevation in neurological diseases. *Fluids and Barriers of the CNS*, 16(1), 9. 10.1186/s12987-019-0129-6 [PubMed: 30967147]
- Boucher Y, & Jain RK (1992). Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse. *Cancer Research*, 52(18), 5110–5114. [PubMed: 1516068]
- Bradley WG (2015). CSF flow in the brain in the context of normal pressure hydrocephalus. *American Journal of Neuroradiology*, 36(5), 831–838. 10.3174/ajnr.A4124 [PubMed: 25355813]
- Brown PD, Davies SL, Speake T, & Millar ID (2004). Molecular mechanisms of cerebrospinal fluid production. *Neuroscience*, 129(4), 957–970. 10.1016/j.neuroscience.2004.07.003 [PubMed: 15561411]
- Bu Y, Chen M, Gao T, Wang X, Li X, & Gao F (2016). Mechanisms of hydrocephalus after intraventricular haemorrhage in adults. *Stroke and Vascular Neurology*, 1(1), 23–27. 10.1136/svn-2015-000003 [PubMed: 28959460]
- Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, & Hansson O (2012). Cerebrospinal fluid levels of β -amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. *Archives of General Psychiatry*, 69(1), 98–106. 10.1001/archgenpsychiatry.2011.155 [PubMed: 22213792]
- Buttram SDW, Wisniewski SR, Jackson EK, Adelson PD, Feldman K, Bayir H, Berger RP, Clark RSB, & Kochanek PM (2007). Multiplex assessment of cytokine and chemokine levels in cerebrospinal

- fluid following severe pediatric traumatic brain injury: Effects of moderate hypothermia. *Journal of Neurotrauma*, 24(11), 1707–1717. 10.1089/neu.2007.0349 [PubMed: 18001201]
- Capel C, Baroncini M, Gondry-Jouet C, Bouzerar R, Czosnyka M, Czosnyka Z, & Balédent O (2018). Cerebrospinal fluid and cerebral blood flows in idiopathic intracranial hypertension. *Acta Neurochirurgica*, 126(Suppl), 237–241. 10.1007/978-3-319-65798-1_48 [PubMed: 29492568]
- Carrano A, Zarco N, Phillipps J, Lara-Velazquez M, Suarez-Meade P, Norton ES, Chaichana KL, Quiñones-Hinojosa A, Asmann YW, & Guerrero-Cazares H (2021). Human cerebrospinal fluid modulates pathways promoting glioblastoma malignancy. *Frontiers in Oncology*, 11, 502. 10.3389/fonc.2021.624145
- Carroll AM, & Brackenridge P (2005). Post-traumatic syringomyelia: A review of the cases presenting in a regional spinal injuries unit in the north east of England over a 5-year period. *Spine*, 30(10), 1206–1210. 10.1097/01.brs.0000162277.76012.0b [PubMed: 15897837]
- Chatterjee K, Atay N, Abler D, Bhargava S, Sahoo P, Rockne RC, & Munson JM (2021). Utilizing dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to analyze interstitial fluid flow and transport in glioblastoma and the surrounding parenchyma in human patients. *Pharmaceutics*, 13(2), 212. 10.3390/pharmaceutics13020212 [PubMed: 33557069]
- Chen S, Shao L, & Ma L (2021). Cerebral edema formation after stroke: Emphasis on blood–brain barrier and the lymphatic drainage system of the brain. *Frontiers in Cellular Neuroscience*, 15, 1–17. 10.3389/fncel.2021.716825
- Christensen J, Wright DK, Yamakawa GR, Shultz SR, & Mychasiuk R (2020). Repetitive mild traumatic brain injury alters Glymphatic clearance rates in limbic structures of adolescent female rats. *Scientific Reports*, 10(1), 6254. 10.1038/s41598-020-63022-7 [PubMed: 32277097]
- Cirrito JR, May PC, O’Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, & Holtzman DM (2003). In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid- β metabolism and half-life. *Journal of Neuroscience*, 23(26), 8844–8853. 10.1523/JNEUROSCI.23-26-08844.2003 [PubMed: 14523085]
- Corneliso RC., Brenna CE., Kingsmor KM., & Munso JM. (2018). Convective forces increase CXCR4-dependent glioblastoma cell invasion in GL261 murine model. *Scientific Reports*, 8(1), 17057. 10.1038/s41598-018-35141-9
- Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore KM, Contarino C, Onengut-Gumuscu S, Farber E, Raper D, Viar KE, Powell RD, Baker W, Dabhi N, Bai R, Cao R, Hu S, Rich SS, Munson JM, ... Kipnis J (2018). Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease. *Nature*, 560(7717), 185–191. 10.1038/s41586-018-0368-8 [PubMed: 30046111]
- Dankier HH, Brown PD, & Praetorius J (2013). Cerebrospinal fluid secretion by the choroid plexus. *Physiological Reviews*, 93(4), 1847–1892. 10.1152/physrev.00004.2013 [PubMed: 24137023]
- Davson H, Hollingsworth G, & Segal MB (1970). The mechanism of drainage of the cerebrospinal fluid. *Brain*, 93(4), 665–678. 10.1093/brain/93.4.665 [PubMed: 5490270]
- Deane R, Du Yan S, Subramanyam RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, ... Zlokovic B (2003). RAGE mediates amyloid- β peptide transport across the blood–brain barrier and accumulation in brain. *Nature Medicine*, 9(7), 907–913. 10.1038/nm890
- Desai B, Hsu Y, Schneller B, Hobbs JG, Mehta AI, & Linninger A (2016). Hydrocephalus: The role of cerebral aquaporin-4 channels and computational modeling considerations of cerebrospinal fluid. *Neurosurgical Focus*, 41(3), E8. 10.3171/2016.7.FOCUS16191
- Dhar R, Chen Y, Hamzehloo A, Kumar A, Heitsch L, He J, Chen L, Slowik A, Strbian D, & Lee J-M (2020). Reduction in CSF volume as an early quantitative biomarker of cerebral edema after ischemic stroke. *Stroke*, 51(2), 462–467. 10.1161/STROKEAHA.119.027895 [PubMed: 31818229]
- Dhar R, Yuan K, Kulik T, Chen Y, Heitsch L, An H, Ford A, & Lee J-M (2016). CSF volumetric analysis for quantification of cerebral edema after hemispheric infarction. *Neurocritical Care*, 24(3), 420–427. 10.1007/s12028-015-0204-z [PubMed: 26438467]

- Eide PK, Vatnehol SAS, Emblem KE, & Ringstad G (2018). Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes. *Scientific Reports*, 8(1), 7194. 10.1038/s41598-018-25666-4 [PubMed: 29740121]
- Enzmann DR, & Pelc NJ (1991). Normal flow patterns of intracranial and spinal cerebrospinal fluid defined with phase-contrast cine MR imaging. *Radiology*, 178(2), 467–474. 10.1148/radiology.178.2.1987610 [PubMed: 1987610]
- Falci SP, Indeck C, & Lammertse DP (2009). Posttraumatic spinal cord tethering and syringomyelia: Surgical treatment and long-term outcome. *Journal of Neurosurgery. Spine*, 11(4), 445–460. 10.3171/2009.4.SPINE09333 [PubMed: 19929342]
- Fantini S, Sassaroli A, Tgavalekos KT, & Kornbluth J (2016). Cerebral blood flow and autoregulation: Current measurement techniques and prospects for noninvasive optical methods. *Neurophotonics*, 3(3), 031411. 10.1117/1.NPh.3.3.031411
- Fischer CM, Neidert MC, Péus D, Ulrich NH, Regli L, Krayenbühl N, & Woernle CM (2014). Hydrocephalus after resection and adjuvant radiochemotherapy in patients with glioblastoma. *Clinical Neurology and Neurosurgery*, 120, 27–31. 10.1016/j.clineuro.2014.02.012 [PubMed: 24731571]
- Fleury ME, Boardman KC, & Swartz MA (2006). Autologous morphogen gradients by subtle interstitial flow and matrix interactions. *Biophysical Journal*, 91(1), 113–121. 10.1529/biophysj.105.080192 [PubMed: 16603487]
- Friedberg MH, Glantz MJ, Klempner MS, Cole BF, & Perides G (1998). Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. *Cancer*, 82(5), 923–930. 10.1002/(sici)1097-0142(19980301)82:5<923::aid-cncr18>3.0.co;2-2 [PubMed: 9486583]
- Friedman JA, Ebersold MJ, & Quast LM (2001). Post-traumatic cerebrospinal fluid leakage. *World Journal of Surgery*, 25(8), 1062–1066. 10.1007/s00268-001-0059-7 [PubMed: 11571972]
- Fukushima Y, Tamura M, Nakagawa H, & Itoh K (2007). Induction of glioma cell migration by vitronectin in human serum and cerebrospinal fluid. *Journal of Neurosurgery*, 107(3), 578–585. 10.3171/JNS-07/09/0578 [PubMed: 17886558]
- Grotzer M, Shalaby T, Fiaschetti G, Baulande S, Gerber N, & Baumgartner M (2015). Detection and quantification of extracellular microRNAs in medulloblastoma. *Journal of Cancer Metastasis and Treatment*, 1(2), 67. 10.4103/2394-4722.157068
- Guan X, Wang W, Wang A, Teng Z, & Han H (2018). Brain interstitial fluid drainage alterations in glioma-bearing rats. *Aging and Disease*, 9(2), 228. 10.14336/AD.2017.0415
- Gutmann R, Leunig M, Feyh J, Goetz AE, Messmer K, Kastenbauer E, & Jain RK (1992). Interstitial hypertension in head and neck tumors in patients: Correlation with tumor size. *Cancer Research*, 52(7), 1993–1995. [PubMed: 1551128]
- Hablitz LM, Pla V, Giannetto M, Vinitzky HS, Stæger FF, Metcalfe T, Nguyen R, Benrais A, & Nedergaard M (2020). Circadian control of brain glymphatic and lymphatic fluid flow. *Nature Communications*, 11(1), 4411. 10.1038/s41467-020-18115-2
- Haessler U, Teo JCM, Foretay D, Renaud P, & Swartz MA (2012). Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber. *Integrative Biology: Quantitative Biosciences from Nano to Macro*, 4(4), 401–409. 10.1039/c1ib00128k [PubMed: 22143066]
- Hakim S, Venegas JG, & Burton JD (1976). The physics of the cranial cavity, hydrocephalus and normal pressure hydrocephalus: Mechanical interpretation and mathematical model. *Surgical Neurology*, 5(3), 187–210. [PubMed: 1257894]
- Han H, Li K, Yan J, Zhu K, & Fu Y (2012). An in vivo study with an MRI tracer method reveals the biophysical properties of interstitial fluid in the rat brain. *Science China. Life Sciences*, 55(9), 782–787. 10.1007/s11427-012-4361-4 [PubMed: 23015126]
- Han H, Shi C, Fu Y, Zuo L, Lee K, He Q, & Han H (2014). A novel MRI tracer-based method for measuring water diffusion in the extracellular space of the rat brain. *IEEE Journal of Biomedical and Health Informatics*, 18(3), 978–983. 10.1109/JBHI.2014.2308279 [PubMed: 24808229]
- Hansso O., Lehman S., Ott M., Zetterber H., & Lewczu P. (2019). Advantages and disadvantages of the use of the CSF amyloid β (A β) 42/40 ratio in the diagnosis of Alzheimer's disease. *Alzheimer's Research & Therapy*, 11(1), 34. 10.1186/s13195-019-0485-0

- Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, & Minthon L (2006). Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. *The Lancet. Neurology*, 5(3), 228–234. 10.1016/S1474-4422(06)70355-6 [PubMed: 16488378]
- Heldin C-H, Rubin K, Pietras K, & Ostman A (2004). High interstitial fluid pressure—An obstacle in cancer therapy. *Nature Reviews. Cancer*, 4(10), 806–813. 10.1038/nrc1456 [PubMed: 15510161]
- Hemley SJ, Bilston LE, Cheng S, & Stoodley MA (2012). Aquaporin-4 expression and blood–spinal cord barrier permeability in canalicular syringomyelia: Laboratory investigation. *Journal of Neurosurgery: Spine*, 17(6), 602–612. 10.3171/2012.9.SPINE1265 [PubMed: 23082850]
- Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H, & Soga T (2009). Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. *Cancer Research*, 69(11), 4918–4925. 10.1158/0008-5472.CAN-08-4806 [PubMed: 19458066]
- Hirose M, Asano M, Watanabe-Matsumoto S, Yamanaka K, Abe Y, Yasui M, Tokuda E, Furukawa Y, & Misawa H (2021). Stagnation of glymphatic interstitial fluid flow and delay in waste clearance in the SOD1-G93A mouse model of ALS. *Neuroscience Research*, 171, 74–82. 10.1016/j.neures.2020.10.006 [PubMed: 33316302]
- Hladky SB, & Barrand MA (2014). Mechanisms of fluid movement into, through and out of the brain: Evaluation of the evidence. *Fluids and Barriers of the CNS*, 11(1), 26. 10.1186/2045-8118-11-26 [PubMed: 25678956]
- Ho C-Y, VandenBussche CJ, Huppman AR, Chaudhry R, & Ali SZ (2015). Cytomorphologic and clinicoradiologic analysis of primary nonhematologic central nervous system tumors with positive cerebrospinal fluid. *Cancer Cytopathology*, 123(2), 123–135. 10.1002/ency.21502 [PubMed: 25487367]
- Hornby C, Mollan SP, Botfield H, O'Reilly MW, & Sinclair AJ (2018). Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. *Journal of Neuro-Ophthalmology: The Official Journal of the North American Neuro-Ophthalmology Society*, 38(4), 522–530. 10.1097/WNO.0000000000000684
- Huff T, Tadi P, & Varacallo M (2021). *Neuroanatomy, Cerebrospinal Fluid*. In StatPearls. StatPearls Publishing <http://www.ncbi.nlm.nih.gov/books/NBK470578/>
- Iiliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, Singh I, Deane R, & Nedergaard M (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *Journal of Neuroscience*, 34(49), 16180–16193. 10.1523/JNEUROSCI.3020-14.2014
- Iiliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, & Nedergaard M (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β . *Science Translational Medicine*, 4(147), 147ra111. 10.1126/scitranslmed.3003748
- Ji C, Yu X, Xu W, Lenahan C, Tu S, & Shao A (2021). The role of glymphatic system in the cerebral edema formation after ischemic stroke. *Experimental Neurology*, 340, 113685. 10.1016/j.expneurol.2021.113685
- Kang J-H, Ryoo N-Y, Shin DW, Trojanowski JQ, & Shaw LM (2014). Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies. *The Korean Journal of Physiology & Pharmacology: Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology*, 18(6), 447–456. 10.4196/kjpp.2014.18.6.447 [PubMed: 25598657]
- Karam Y, Hitchon PW, Mhanna NE, He W, & Noeller J (2014). Post-traumatic syringomyelia: Outcome predictors. *Clinical Neurology and Neurosurgery*, 124, 44–50. 10.1016/j.clineuro.2014.06.007 [PubMed: 25016238]
- Kingsmore KM, Logsdon DK, Floyd DH, Peirce SM, Purow BW, & Munson JM (2016). Interstitial flow differentially increases patient-derived glioblastoma stem cell invasion via CXCR4, CXCL12, and CD44-mediated mechanisms. *Integrative Biology: Quantitative Biosciences from Nano to Macro*, 8(12), 1246–1260. 10.1039/c6ib00167j [PubMed: 27775742]
- Kingsmore KM, Vaccari A, Abler D, Cui SX, Epstein FH, Rockne RC, Acton ST, & Munson JM (2018). MRI analysis to map interstitial flow in the brain tumor microenvironment. *APL Bioengineering*, 2(3), 031905. 10.1063/1.5023503

- Kirchhoff C, Buhmann S, Bogner V, Stegmaier J, Leidel BA, Braunstein V, Mutschler W, & Biberthaler P (2008). Cerebrospinal IL-10 concentration is elevated in non-survivors as compared to survivors after severe traumatic brain injury. *European Journal of Medical Research*, 13(10), 464–468. [PubMed: 19008173]
- Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, & Stevens JC (2001). Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the quality standards Subcommittee of the American Academy of Neurology. *Neurology*, 56(9), 1143–1153. 10.1212/wnl.56.9.1143 [PubMed: 11342678]
- Koleva M, & De Jesus O (2022). Hydrocephalus. In StatPearls. StatPearls Publishing <http://www.ncbi.nlm.nih.gov/books/NBK560875/>
- Korbecki A, Zimny A, Podgorski P, Siatkiewicz M, & Bladowska J (2019). Imaging of cerebrospinal fluid flow: Fundamentals, techniques, and clinical applications of phase-contrast magnetic resonance imaging. *Polish Journal of Radiology*, 84, e240–e250. 10.5114/pjr.2019.86881 [PubMed: 31481996]
- Kvietys PR, & Granger DN (2010). Role of intestinal lymphatics in interstitial volume regulation and transmucosal water transport. *Annals of the New York Academy of Sciences*, 1207(Suppl. 1), E29–E43. 10.1111/j.1749-6632.2010.05709.x [PubMed: 20961304]
- Lagos-Quintana M., Rauhut R., Lendeckel W., & Tuschl T. (2001). Identification of novel genes coding for small expressed RNAs. *Science (New York, N.Y.)*, 294(5543), 853–858. 10.1126/science.1064921 [PubMed: 11679670]
- Lee DS, Suh M, Sarker A, & Choi Y (2020). Brain glymphatic/lymphatic imaging by MRI and PET. *Nuclear Medicine and Molecular Imaging*, 54(5), 207–223. 10.1007/s13139-020-00665-4 [PubMed: 33088350]
- Lee I, Boucher Y, & Jain RK (1992). Nicotinamide can lower tumor interstitial fluid pressure: Mechanistic and therapeutic implications. *Cancer Research*, 52(11), 3237–3240. [PubMed: 1534273]
- Lee W-J, Jung K-H, Park H-M, Sohn C-H, Lee S-T, Park K-I, Chu K, Jung K-Y, Kim M, Lee SK, & Roh J-K (2019). Periodicity of cerebral flow velocity during sleep and its association with white-matter hyperintensity volume. *Scientific Reports*, 9(1), 15510. 10.1038/s41598-019-52029-4
- Li L, Chopp M, Ding G, Davoodi-Bojd E, Zhang L, Li Q, Zhang Y, Xiong Y, & Jiang Q (2020). MRI detection of impairment of glymphatic function in rat after mild traumatic brain injury. *Brain Research*, 1747, 147062. 10.1016/j.brainres.2020.147062
- Locasale JW, Melman T, Song S, Yang X, Swanson KD, Cantley LC, Wong ET, & Asara JM (2012). Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma. *Molecular & Cellular Proteomics: MCP*, 11(6), M111.014688. 10.1074/mcp.M111.014688
- Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, & Kipnis J (2015). Structural and functional features of central nervous system lymphatic vessels. *Nature*, 523(7560), 337–341. 10.1038/nature14432 [PubMed: 26030524]
- Lv D, Li J, Li H, Fu Y, & Wang W (2017). Imaging and quantitative analysis of the interstitial space in the caudate nucleus in a rotenone-induced rat model of Parkinson's disease using tracer-based MRI. *Aging and Disease*, 8(1), 1–6. 10.14336/AD.2016.0625 [PubMed: 28203477]
- Ma Q, Ineichen BV, Detmar M, & Proulx ST (2017). Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice. *Nature Communications*, 8(1), 1434. 10.1038/s41467-017-01484-6
- Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S-K, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, ... Blennow K (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA*, 302(4), 385–393. 10.1001/jama.2009.1064 [PubMed: 19622817]
- Mestre H, Hablitz LM, Xavier AL, Feng W, Zou W, Pu T, Monai H, Murlidharan G, Castellanos Rivera RM, Simon MJ, Pike MM, Plá V, Du T, Kress BT, Wang X, Plog BA, Thrane AS, Lundgaard I, Abe Y, ... Nedergaard M (2018). Aquaporin-4-dependent glymphatic solute transport in the rodent brain. *eLife*, 7, e40070. 10.7554/eLife.40070

- Mestre H, Tithof J, Du T, Song W, Peng W, Sweeney AM, Olveda G, Thomas JH, Nedergaard M, & Kelley DH (2018). Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. *Nature Communications*, 9(1), 4878. 10.1038/s41467-018-07318-3
- Mohammad SA, Osman NM, & Ahmed KA (2019). The value of CSF flow studies in the management of CSF disorders in children: A pictorial review. *Insights Into Imaging*, 10, 3. 10.1186/s13244-019-0686-x [PubMed: 30689061]
- Mollan SP, Ali F, Hassan-Smith G, Botfield H, Friedman DI, & Sinclair AJ (2016). Evolving evidence in adult idiopathic intracranial hypertension: Pathophysiology and management. *Journal of Neurology, Neurosurgery, and Psychiatry*, 87(9), 982–992. 10.1136/jnnp-2015-311302 [PubMed: 26888960]
- Munson JM, Bellamkonda RV, & Swartz MA (2013). Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. *Cancer Research*, 73(5), 1536–1546. 10.1158/0008-5472.CAN-12-2838 [PubMed: 23271726]
- Munson JM, & Shieh AC (2014). Interstitial fluid flow in cancer: Implications for disease progression and treatment. *Cancer Management and Research*, 6, 317–328. 10.2147/CMAR.S65444 [PubMed: 25170280]
- Nakada T, & Kwee IL (2019). Fluid dynamics inside the brain barrier: Current concept of interstitial flow, glymphatic flow, and cerebrospinal fluid circulation in the brain. *The Neuroscientist*, 25(2), 155–166. 10.1177/1073858418775027 [PubMed: 29799313]
- Nakamizo S, Sasayama T, Shinohara M, Irino Y, Nishiumi S, Nishihara M, Tanaka H, Tanaka K, Mizukawa K, Itoh T, Taniguchi M, Hosoda K, Yoshida M, & Kohmura E (2013). GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. *Journal of Neuro-Oncology*, 113(1), 65–74. 10.1007/s11060-013-1090-x [PubMed: 23456655]
- Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, Liu C-M, Deangelis LM, & Omuro A (2013). Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. *Neurology*, 80(17), 1598–1605; discussion 1603. 10.1212/WNL.0b013e31828f183f [PubMed: 23553479]
- Nedergaard M (2013). Neuroscience. Garbage truck of the brain. *Science (New York, N.Y.)*, 340(6140), 1529–1530. 10.1126/science.1240514 [PubMed: 23812703]
- Nitz WR, Bradley WG, Watanabe AS, Lee RR, Burgoyne B, O'Sullivan RM, & Herbst MD (1992). Flow dynamics of cerebrospinal fluid: Assessment with phase-contrast velocity MR imaging performed with retrospective cardiac gating. *Radiology*, 183(2), 395–405. 10.1148/radiology.183.2.1561340 [PubMed: 1561340]
- O'Reilly MW., Westgate CSJ., Hornby C., Botfield H., Taylor AE., Markey K., Mitchell JL., Scotton WJ., Mollan SP., Yiangou A., Jenkinson C., Gilligan LC., Sherlock M., Gibney J., Tomlinson JW., Lavery GG., Hodson DJ., Arlt W., & Sinclair AJ. (2019). A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. *JCI Insight*, 4(6), e125348. 10.1172/jci.insight.125348
- Osman AFI (2019). A multi-parametric MRI-based radiomics signature and a practical ML model for stratifying glioblastoma patients based on survival toward precision oncology. *Frontiers in Computational Neuroscience*, 13, 58. 10.3389/fncom.2019.00058 [PubMed: 31507398]
- Pan C, Diplas BH, Chen X, Wu Y, Xiao X, Jiang L, Geng Y, Xu C, Sun Y, Zhang P, Wu W, Wang Y, Wu Z, Zhang J, Jiao Y, Yan H, & Zhang L (2019). Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. *Acta Neuropathologica*, 137(2), 297–306. 10.1007/s00401-018-1936-6 [PubMed: 30460397]
- Papadopoulos MC, & Verkman AS (2013). Aquaporin water channels in the nervous system. *Nature Reviews. Neuroscience*, 14(4), 265–277. 10.1038/nrn3468 [PubMed: 23481483]
- Polacheck WJ, Charest JL, & Kamm RD (2011). Interstitial flow influences direction of tumor cell migration through competing mechanisms. *Proceedings of the National Academy of Sciences of the United States of America*, 108(27), 11115–11120. 10.1073/pnas.1103581108
- Pollay M (2010). The function and structure of the cerebrospinal fluid outflow system. *Cerebrospinal Fluid Research*, 7(1), 9. 10.1186/1743-8454-7-9 [PubMed: 20565964]

- Qazi H, Shi Z-D, & Tarbell JM (2011). Fluid shear stress regulates the invasive potential of glioma cells via modulation of migratory activity and matrix metalloproteinase expression. *PLoS One*, 6(5), e20348. 10.1371/journal.pone.0020348
- Rekate HL (2009). A contemporary definition and classification of hydrocephalus. *Seminars in Pediatric Neurology*, 16(1), 9–15. 10.1016/j.spen.2009.01.002 [PubMed: 19410151]
- Saido T, & Leissring MA (2012). Proteolytic degradation of amyloid β -protein. *Cold Spring Harbor Perspectives in Medicine*, 2(6), a006379. 10.1101/cshperspect.a006379
- Sakka L, Coll G, & Chazal J (2011). Anatomy and physiology of cerebrospinal fluid. *European Annals of Otorhinolaryngology, Head and Neck Diseases*, 128(6), 309–316. 10.1016/j.anorl.2011.03.002 [PubMed: 22100360]
- Santos CRA, Duarte AC, Quintela T, Tomas J, Albuquerque T, Marques F, Palha JA, & Gonçalves I (2017). The choroid plexus as a sex hormone target: Functional implications. *Frontiers in Neuroendocrinology*, 44, 103–121. 10.1016/j.yfrne.2016.12.002 [PubMed: 27998697]
- Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, & Medical Research Council Cognitive Function and Ageing Study. (2009). Age, neuropathology, and dementia. *The New England Journal of Medicine*, 360(22), 2302–2309. 10.1056/NEJMoa0806142 [PubMed: 19474427]
- Schröder J, Kaiser E, Schönknecht P, Hunt A, Thomann PA, Pantel J, & Schröder J (2008). CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease. *Zeitschrift Fur Gerontologie Und Geriatrie*, 41(6), 497–501. 10.1007/s00391-007-0492-9 [PubMed: 18327693]
- Segal MB (1993). Extracellular and cerebrospinal fluids. *Journal of Inherited Metabolic Disease*, 16(4), 617–638. 10.1007/BF00711896 [PubMed: 8412010]
- Semple BD, Bye N, Rancan M, Ziebell JM, & Morganti-Kossmann MC (2010). Role of CCL2 (MCP-1) in traumatic brain injury (TBI): Evidence from severe TBI patients and CCL2/ mice. *Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism*, 30(4), 769–782. 10.1038/jcbfm.2009.262 [PubMed: 20029451]
- Shah AD, Bouchard MJ, & Shieh AC (2015). Interstitial fluid flow increases hepatocellular carcinoma cell invasion through CXCR4/CXCL12 and MEK/ERK signaling. *PLoS One*, 10(11), e0142337. 10.1371/journal.pone.0142337
- Shi C, Lei Y, Han H, Zuo L, Yan J, He Q, Yuan L, Liu H, Xu G, & Xu W (2015). Transportation in the interstitial space of the brain can be regulated by neuronal excitation. *Scientific Reports*, 5(1), 17673. 10.1038/srep17673
- Shi R, Wang P-Y, Li X-Y, Chen J-X, Li Y, Zhang X-Z, Zhang C-G, Jiang T, Li W-B, Ding W, & Cheng S-J (2015). Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. *Oncotarget*, 6(29), 26971–26981.
- Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, & Zlokovic BV (2000). Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *The Journal of Clinical Investigation*, 106(12), 1489–1499. 10.1172/JCI10498 [PubMed: 11120756]
- Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, & Swartz MA (2007). Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. *Cancer Cell*, 11(6), 526–538. 10.1016/j.ccr.2007.04.020 [PubMed: 17560334]
- Siekkinen R, Teuho J, Smith NAS, Fenwick A, Kirjavainen AK, Koskensalo K, Saraste A, & Teräs M (2020). Study of the effect of reconstruction parameters for myocardial perfusion imaging in PET with a novel flow phantom. *Frontiers in Physics*, 8, 148. 10.3389/fphy.2020.00148
- Silva I, Silva J, Ferreira R, & Trigo D (2021). Glymphatic system, AQP4, and their implications in Alzheimer's disease. *Neurological Research and Practice*, 3(1), 5. 10.1186/s42466-021-00102-7 [PubMed: 33499944]
- Simats A, García-Berrocso T, Ramiro L, Giralto D, Gill N, Penalba A, Bustamante A, Rosell A, & Montaner J (2018). Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology. *Scientific Reports*, 8(1), 7899. 10.1038/s41598-018-26237-3 [PubMed: 29784938]

- Smith RM, Garza I, & Robertson CE (2015). Chronic CSF leak causing syringomyelia and pseudo-Arnold-Chiari malformation. *Neurology*, 85(22), 1994. 10.1212/WNL.0000000000002178 [PubMed: 26628487]
- Spijkerman JM., Geurts LJ., Siero JCW., Hendrikse J., Luijten PR., & Zwanenburg JJM. (2019). Phase contrast MRI measurements of net cerebrospinal fluid flow through the cerebral aqueduct are confounded by respiration. *Journal of Magnetic Resonance Imaging*, 49(2), 433–444. 10.1002/jmri.26181 [PubMed: 29741818]
- Stiebel-Kalish H, Eyal S, & Steiner I (2013). The role of aquaporin-1 in idiopathic and drug-induced intracranial hypertension. *Medical Hypotheses*, 81(6), 1059–1062. 10.1016/j.mehy.2013.10.002 [PubMed: 24169407]
- Stine CA, & Munson JM (2022). Autologous gradient formation under differential interstitial fluid flow environments. *Biophysica*, 2(1), 16–33. 10.3390/biophysica2010003
- Sussman J, Leach M, Greaves M, Malia R, & Davies-Jones GA (1997). Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension. *Journal of Neurology, Neurosurgery, and Psychiatry*, 62(3), 229–233. 10.1136/jnnp.62.3.229 [PubMed: 9069476]
- Sykova E, Vorisek I, Antonova T, Mazel T, Meyer-Luehmann M, Jucker M, Hajek M, Ort M, & Bures J (2005). Changes in extracellular space size and geometry in APP23 transgenic mice: A model of Alzheimer's disease. *Proceedings of the National Academy of Sciences of Sciences of the United States of America*, 102(2), 479–484. 10.1073/pnas.0408235102
- Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, & Khasraw M (2020). Management of glioblastoma: State of the art and future directions. *CA: A Cancer Journal for Clinicians*, 70(4), 299–312. 10.3322/caac.21613 [PubMed: 32478924]
- Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Ménard J, Zetterberg H, Wisniewski T, & de Leon MJ (2015). Clearance systems in the brain—Implications for Alzheimer disease. *Nature Reviews Neurology*, 11(8), 457–470. 10.1038/nrneurol.2015.119 [PubMed: 26195256]
- Tawfik AM, ElSOROgy L, Abdelghaffar R, Naby AA, & Elmenshawi I (2017). Phase-contrast MRI CSF flow measurements for the diagnosis of normal-pressure hydrocephalus: Observer agreement of velocity versus volume parameters. *American Journal of Roentgenology*, 208(4), 838–843. 10.2214/AJR.16.16995 [PubMed: 28140607]
- Telano LN, & Baker S (2021). Physiology, cerebral spinal fluid. In StatPearls. StatPearls Publishing <http://www.ncbi.nlm.nih.gov/books/NBK519007/>
- Tobimatsu Y, Nihei R, Kimura T, Suyama T, Kimura H, Tobimatsu H, & Shirakawa T (1995). A quantitative analysis of cerebrospinal fluid flow in post-traumatic syringomyelia. *Spinal Cord*, 33(4), 203–207. 10.1038/sc.1995.45
- Uzair-Ul-Haq M, Ahmed A, Mustansar Z, Shaukat A, Margetts L, & Nadeem F (n.d.). Analysis of growing tumor on the flow velocity of cerebrospinal fluid in human brain using computational modeling and fluid-structure interaction. (p. 18).
- Vaquero J, Hassan R, Fernandez C, Rodríguez-Boto G, & Zurita M (2017). Cell therapy as a new approach to the treatment of posttraumatic syringomyelia. *World Neurosurgery*, 107, 1047.e5–1047.e8. 10.1016/j.wneu.2017.08.019
- Veening JG, & Barendregt HP (2010). The regulation of brain states by neuroactive substances distributed via the cerebrospinal fluid: A review. *Cerebrospinal Fluid Research*, 7, 1. 10.1186/1743-8454-7-1 [PubMed: 20157443]
- Verkman AS, Tradtrantip L, Smith AJ, & Yao X (2017). Aquaporin water channels and hydrocephalus. *Pediatric Neurosurgery*, 52(6), 409–416. 10.1159/000452168 [PubMed: 27978530]
- Virdee J, Larcombe S, Vijay V, Sinclair AJ, Dayan M, & Mollan SP (2020). Reviewing the recent developments in idiopathic intracranial hypertension. *Ophthalmology and therapy*, 9(4), 767–781. 10.1007/s40123-020-00296-0 [PubMed: 32902722]
- Wang D, Nykanen M, Yang N, Winlaw D, North K, Verkman AS, & Owler BK (2011). Altered cellular localization of aquaporin-1 in experimental hydrocephalus in mice and reduced ventriculomegaly in aquaporin-1 deficiency. *Molecular and Cellular Neuroscience*, 46(1), 318–324. 10.1016/j.mcn.2010.10.003 [PubMed: 21040788]

- Wattmo C, Blennow K, & Hansson O (2020). Cerebro-spinal fluid biomarker levels: Phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. *BMC Neurology*, 20(1), 10. 10.1186/s12883-019-1591-0 [PubMed: 31918679]
- Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, & Wang K (2010). The microRNA spectrum in 12 body fluids. *Clinical Chemistry*, 56(11), 1733–1741. 10.1373/clinchem.2010.147405 [PubMed: 20847327]
- Welter M, & Rieger H (2013). Interstitial fluid flow and drug delivery in vascularized tumors: A computational model. *PLoS One*, 8(8), e70395. 10.1371/journal.pone.0070395
- Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, & Nedergaard M (2013). Sleep drives metabolite clearance from the adult brain. *Science*, 342(6156), 373–377. 10.1126/science.1241224 [PubMed: 24136970]
- Xiong G, Elkind JA, Kundu S, Smith CJ, Antunes MB, Tamashiro E, Kofonow JM, Mitala Christina M., Stein SC, Grady MS, Einhorn E, Cohen NA, & Cohen AS (2014). Traumatic brain injury-induced ependymal ciliary loss decreases cerebral spinal fluid flow. *Journal of Neurotrauma*, 31(16), 1396–1404. 10.1089/neu.2013.3110 [PubMed: 24749541]
- Yeo J, Cheng S, Hemley S, Lee BB, Stoodley M, & Bilston L (2017). Characteristics of CSF velocity-time profile in posttraumatic syringomyelia. *American Journal of Neuroradiology*, 38(9), 1839–1844. 10.3174/ajnr.A5304 [PubMed: 28729294]
- Yousef MI, Abd El Mageed AE, Yassin AEN, & Shaaban MH (2016). Use of cerebrospinal fluid flow rates measured by phase-contrast MR to differentiate normal pressure hydrocephalus from involutional brain changes. *The Egyptian Journal of Radiology and Nuclear Medicine*, 47(3), 999–1008. 10.1016/j.ejrn.2016.04.001
- Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, & Talasz A (2018). The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, 24(15), 3528–3538. 10.1158/1078-0432.CCR-17-3837 [PubMed: 29776953]




FIGURE 1.

Overview of glymphatic clearance. The glymphatic system drains cerebrospinal fluid (CSF) and solutes through the brain via its periarterial flow pathway, while the CSF is exchanged with IF, allowing interstitial solutes to be cleared out of the parenchyma via the perivenous pathway. Figure was created using Biorender with license to JMM.




FIGURE 2.

The collection of CSF and potential analytes. The CSF contains several potential molecular biomarkers including cells, DNA, RNA and protein and other metabolites that can be used to diagnose and follow disease. BEAMing, beads, emulsion, amplification, and magnetics; ddPCR, droplet digital PCR; PCR, polymerase chain reaction; qRT-PCR, quantitative real-time-PCR; NGS, next-generation sequencing. Figure was created using Biorender with license to JMM.

TABLE 1

The summarizing the different methods of imaging and sampling

	CSF	IF
Method of imaging	MRI, ASL, 3D-SPACE, PET	MRI, PET, SPECT, intravital microscopy, autoradiography, transcranial Doppler
Method of sampling	Brain ventricle, lumbar puncture	Microdialysis, surgical sampling

Abbreviations: CSF, cerebrospinal fluid; IF, interstitial fluid.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 2

Fluid flow changes in different brain disorders (as compared to healthy brain)

Type of disease	IF flow rate	CSF flow rate
Alzheimer's disease	↓ (Sykova et al., 2005)	↑ (Attier-Zmudka et al., 2019)
Brain tumor	↑ (Kingsmore et al., 2018)	↑ (Uzair-Ul-Haq et al., n.d.)
Traumatic brain injury	N/A	↓ (Xiong et al., 2014)
Idiopathic intracranial hypertension	N/A	Acute patients ↑, Chronic patients ↓ (Akay et al., 2015; Belal et al., 2020)
Normal pressure hydrocephalus	N/A	↑ (Ahmad et al., 2021; Bradley, 2015; Tawfik et al., 2017)
Ischemic stroke	N/A	↑ (Dhar et al., 2020)
Post-traumatic syringomyelia	N/A	↓ (Yeo et al., 2017)